Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Trilaciclib significantly reduced the incidence of chemotherapy-induced myelosuppression in patients with small-cell lung cancer (SCLC) or breast cancer. It lowered the occurrence of severe neutropenia (19.3% vs. 42.2%; odds ratio (OR) = 0.31), febrile neutropenia (3.22% vs. 6.72%; OR = 0.47), and anemia (20.5% vs. 38.2%; OR = 0.38) compared to the control group.
• The need for supportive care interventions was also reduced in the Trilaciclib group, including lower use of erythropoiesis-stimulating agents (4.03% vs. 11.8%; OR = 0.31), granulocyte-colony stimulating factors (37.0% vs. 53.5%; OR = 0.52), and red blood cell transfusions (19.8% vs. 29.9%; OR = 0.56).
• There was no significant difference between the Trilaciclib and control groups in terms of overall response rate (ORR), overall survival (OS), or progression-free survival (PFS), indicating that Trilaciclib does not affect the efficacy of chemotherapy.
• Adverse Events (AEs) and Severe Adverse Events (SAEs): The occurrence of chemotherapy-induced AEs, such as diarrhea, fatigue, nausea, and vomiting, was reported to be the same in both the Trilaciclib and control groups, indicating no increase in risk associated with Trilaciclib use during chemotherapy.
• Safety Concerns in Specific Populations: There were no specific safety concerns or adverse effects noted in different population types or subgroups, and Trilaciclib demonstrated an acceptable safety profile across the included studies involving adult patients with SCLC or breast cancer.
• The studies focused on adult patients with small-cell lung cancer or breast cancer undergoing chemotherapy, showing that Trilaciclib significantly reduced chemotherapy-induced myelosuppression and the need for supportive care interventions, with no reported differences in effectiveness or safety across different population subgroups.